215 related articles for article (PubMed ID: 36168189)
41. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
Hernandez I; Zhang Y
J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
[TBL] [Abstract][Full Text] [Related]
42. Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project.
Schini M; Vilaca T; Vittinghoff E; Lui LY; Ewing SK; Thompson AR; Bauer DC; Bouxsein ML; Black DM; Eastell R
J Bone Miner Res; 2024 May; 39(5):544-550. PubMed ID: 38501786
[TBL] [Abstract][Full Text] [Related]
43. An Evaluation of Treatment Patterns for Osteoporosis and Outcomes After a Fragility Fracture in a Real-World Setting.
Singer AJ; Williams SA; Pearman L; Wang Y; Pyrih N; Jeray K
J Orthop Trauma; 2023 Apr; 37(4):e159-e164. PubMed ID: 36730766
[TBL] [Abstract][Full Text] [Related]
44. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
[TBL] [Abstract][Full Text] [Related]
45. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
46. Decreased Mortality and Subsequent Fracture Risk in Patients With a Major and Hip Fracture After the Introduction of a Fracture Liaison Service: A 3-Year Follow-Up Survey.
Vranken L; de Bruin IJA; Driessen AHM; Geusens PPM; Eisman JA; Center JR; van der Velde RY; Janzing HMJ; Kaarsemaker S; van den Bergh JP; Wyers CE
J Bone Miner Res; 2022 Oct; 37(10):2025-2032. PubMed ID: 36087016
[TBL] [Abstract][Full Text] [Related]
47. Disparities in osteoporosis treatments.
Liu Z; Weaver J; de Papp A; Li Z; Martin J; Allen K; Hui S; Imel EA
Osteoporos Int; 2016 Feb; 27(2):509-19. PubMed ID: 26216226
[TBL] [Abstract][Full Text] [Related]
48. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
49. Treatment for older men with fractures.
Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
[TBL] [Abstract][Full Text] [Related]
50. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
51. Osteoporosis management in older patients who experienced a fracture.
Oertel MJ; Graves L; Al-Hihi E; Leonardo V; Hopkins C; DeSouza K; Bhattacharya RK
Clin Interv Aging; 2016; 11():1111-6. PubMed ID: 27578967
[TBL] [Abstract][Full Text] [Related]
52. FRAIL Questionnaire Screening Tool and Short-Term Outcomes in Geriatric Fracture Patients.
Gleason LJ; Benton EA; Alvarez-Nebreda ML; Weaver MJ; Harris MB; Javedan H
J Am Med Dir Assoc; 2017 Dec; 18(12):1082-1086. PubMed ID: 28866353
[TBL] [Abstract][Full Text] [Related]
53. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
54. Frailty Phenotype and Healthcare Costs and Utilization in Older Men.
Ensrud KE; Kats AM; Schousboe JT; Taylor BC; Vo TN; Cawthon PM; Hoffman AR; Langsetmo L;
J Am Geriatr Soc; 2020 Sep; 68(9):2034-2042. PubMed ID: 32402097
[TBL] [Abstract][Full Text] [Related]
55. The clinician's guide to prevention and treatment of osteoporosis.
LeBoff MS; Greenspan SL; Insogna KL; Lewiecki EM; Saag KG; Singer AJ; Siris ES
Osteoporos Int; 2022 Oct; 33(10):2049-2102. PubMed ID: 35478046
[TBL] [Abstract][Full Text] [Related]
56. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
57. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Kim M; Lin TC; Arora T; Zhao H; Balasubramanian A; Stad RK; O'Kelly J; Spangler L; Bradbury BD; Curtis JR
J Bone Miner Res; 2023 Jun; 38(6):829-840. PubMed ID: 37088886
[TBL] [Abstract][Full Text] [Related]
58. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
[TBL] [Abstract][Full Text] [Related]
59. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.
Avenell A; Mak JC; O'Connell D
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD000227. PubMed ID: 24729336
[TBL] [Abstract][Full Text] [Related]
60. Incident fracture associated with increased risk of mortality even after adjusting for frailty status in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study.
Iki M; Fujita Y; Tamaki J; Kouda K; Yura A; Sato Y; Moon JS; Harano A; Hazaki K; Kajita E; Hamada M; Arai K; Tomioka K; Okamoto N; Kurumatani N
Osteoporos Int; 2017 Mar; 28(3):871-880. PubMed ID: 27752744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
